India unveils world's first nasal vaccine for Covid (Photo for representation)
The booster dose of Bharat Biotech’s Covid-19 nasal vaccine iNCOVACC was given emergency use authorisation (EUA) by the Drugs Controller General of India (DCGI).
The EUA is reported to have been granted for restricted emergency use as the third dose for adults irrespective of having been administered Covaxin or Covishield vaccine doses.
According to the Hyderabad-based vaccine manufacturer, the nasal route has excellent potential for vaccination due to the organised immune systems of the nasal mucosa.
iNCOVACC is India’s first nasal vaccine developed against Covid-19. The nasal vaccine can be taken after six months of the second dose. As this is non-invasive and needle-free, it becomes easy to administer.
The intranasal immunisation of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus. The booster dose will thereby protect against disease, infection, and transmission.
Taiwan's military is prioritising combat readiness as a key aspect of deterrence due to escalating…
Calling for an increase in the speed of development, Prime Minister Narendra Modi said on…
The Scottish Government has reaffirmed its commitment to supporting religious freedom and human rights for…
Tara Chand Baloch, the President of the Baloch American Congress and a former Cabinet minister…
In a groundbreaking study, researchers from McGill University have identified nine biological markers in the…
India, in a firm and unequivocal statement at the United Nations Security Council (UNSC), accused…
